featured
Satralizumab Reduces Relapse in Neuromyelitis Optica Spectrum Disorder
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder
N. Engl. J. Med 2019 Nov 28;381(22)2114-2124, T Yamamura, I Kleiter, K Fujihara, J Palace, B Greenberg, B Zakrzewska-Pniewska, F Patti, CP Tsai, A Saiz, H Yamazaki, Y Kawata, P Wright, J De SezeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.